José Antonio Sacristán
José Antonio Sacristán
Senior Medical Director, Lilly Spain
Verified email at
Cited by
Cited by
Adherencia y persistencia terapéutica: causas, consecuencias y estrategias de mejora
T Dilla, A Valladares, L Lizán, JA Sacristán
Atención primaria 41 (6), 342, 2009
Allopurinol hypersensitivity syndrome: a review
F Arellano, JA Sacristán
Annals of Pharmacotherapy 27 (3), 337-343, 1993
Problems and solutions in calculating quality-adjusted life years (QALYs)
L Prieto, JA Sacristán
Health and quality of life outcomes 1, 1-8, 2003
¿ Qué es una tecnología sanitaria eficiente en España?
JA Sacristán, J Oliva, JD Llano, L Prieto, JL Pinto
Gaceta Sanitaria 16, 334-343, 2002
Patient-centered medicine and patient-oriented research: improving health outcomes for individual patients
JA Sacristán
BMC medical informatics and decision making 13, 1-8, 2013
Patient involvement in clinical research: why, when, and how
JA Sacristán, A Aguarón, C Avendaño-Solá, P Garrido, J Carrión, ...
Patient preference and adherence, 631-640, 2016
What is an efficient health technology in Spain?
JA Sacristán, J Oliva, J Del Llano, L Prieto, JL Pinto
Gaceta sanitaria 16 (4), 334-343, 2002
Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: an open-label, prospective, nonrandomized …
C Turbí, G Herrero-Beaumont, JC Acebes, A Torrijos, J Graña, R Miguélez, ...
Clinical therapeutics 26 (2), 245-256, 2004
Farmacoeconomía: evaluación económica de medicamentos
JAS del Castillo, XB Llach, JR Forns
EDIMSA, 1995
Evaluation of pharmacoeconomic studies: utilization of a checklist
JA Sacristán, J Soto, I Galende
Annals of pharmacotherapy 27 (9), 1126-1133, 1993
The safety of olanzapine compared with other antipsychotic drugs: results of an observational prospective study in patients with schizophrenia (EFESO Study)
JC Gomez, JA Sacristan, J Hernandez, A Breier, PR Carrasco, CA Saiz, ...
Journal of Clinical Psychiatry 61 (5), 335-343, 2000
Evaluación económica en medicina
JA Sacristán, V Ortún, J Rovira, L Prieto, F García-Alonso
Medicina clínica 122 (10), 379-382, 2004
Psychometric validation of a generic health-related quality of life measure (EQ-5D) in a sample of schizophrenic patients
L Prieto, JA Sacristán, JA Hormaechea, A Casado, X Badia, JC Gómez
Current Medical Research and Opinion 20 (6), 827-835, 2004
Análisis coste-efectividad en la evaluación económica de intervenciones sanitarias
L Prieto, JA Sacristán, F Antoñanzas, C Rubio-Terrés, JL Pinto, J Rovira
Medicina clínica 122 (13), 505-510, 2004
Metamizole: reassessment of its therapeutic role
F Arellano, JA Sacristán
European journal of clinical pharmacology 38, 617-619, 1990
Subjective response to antipsychotic treatment and compliance in schizophrenia. A naturalistic study comparing olanzapine, risperidone and haloperidol (EFESO Study)
I García-Cabeza, JC Gómez, JA Sacristán, E Edgell, ...
BMC psychiatry 1, 1-8, 2001
A Rasch model analysis to test the cross‐cultural validity of the EuroQoL‐5D in the Schizophrenia Outpatient Health Outcomes Study
L Prieto, D Novick, JA Sacristan, ET Edgell, J Alonso, SOHO Study Group
Acta Psychiatrica Scandinavica 107, 24-29, 2003
Clinical research and medical care: towards effective and complete integration
JA Sacristán
BMC medical research methodology 15, 1-7, 2015
Análisis de costes y resultados en la evaluación económica de las intervenciones sanitarias
L Prieto, JA Sacristána, JL Pinto, X Badia, F Antoñanzas, J del Llano
Medicina clínica 122 (11), 423-429, 2004
Effectiveness of mRNA vaccine boosters against infection with the SARS-CoV-2 omicron (B. 1.1. 529) variant in Spain: a nationwide cohort study
S Monge, A Rojas-Benedicto, C Olmedo, C Mazagatos, MJ Sierra, ...
The Lancet Infectious Diseases 22 (9), 1313-1320, 2022
The system can't perform the operation now. Try again later.
Articles 1–20